Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

bluebird unveils topline interim data from Starbeam study of Lenti-D in CALD bluebird bio has released topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating its investigational gene therapy Lenti-D in under-18 boys with cerebral adrenoleukodystrophy (CALD).
Contract Research & Services > Clinical Trials > News
Roche's emicizumab shows substantial reduction in bleeds in phase III studies By PBR Staff Writer
Roche’s haemophilia A drug emicizumab has showed a significant effect in the phase III Haven 1 and Haven 2 studies.
Contract Research & Services > Clinical Trials > News Novartis’ heart drug canakinumab meets primary endpoint in phase III study By PBR Staff Writer
Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Novartis’ heart drug canakinumab meets primary endpoint in phase III study
By PBR Staff Writer
Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study.
Contract Research & Services > Clinical Trials > News
GSK’s shingles vaccine Shingrix succeeds in phase 3 revaccination trial
By PBR Staff Writer
GSK’s shingles vaccine candidate Shingrix (HZ/su) met its primary objective of inducing a strong immune response in older patients in a phase 3 revaccination trial.
Contract Research & Services > Clinical Trials > News
ImmunoCellular to suspend patient randomization in ICT-107 phase 3 trial
ImmunoCellular Therapeutics has provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma.
Contract Research & Services > Clinical Trials > News
Pfizer initiates phase 1 study of streptococcus vaccine
Pfizer has commenced a phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine for the prevention of Group B Streptococcus (GBS) infection.
Contract Research & Services > Clinical Trials > News
Seattle Genetics scraps leukemia drug trial over safety concerns
By PBR Staff Writer
Seattle Genetics has suspended its phase 3 acute myeloid leukemia (AML) trial of vadastuximab talirine (SGN-CD33A) due to a higher rate of death incidents.
Contract Research & Services > Clinical Trials > News
Novartis' Cosentyx generates positive data in ankylosing spondylitis and psoriatic arthritis
By PBR Staff Writer
Novartis' Cosentyx has demonstrated sustained improvements in signs and symptoms for both active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA) in up to 80% of patients at three years.
Contract Research & Services > Clinical Trials > News
Regulus to discontinue clinical development of HCV candidate RG-101
By PBR Staff Writer
Regulus Therapeutics said it intends to discontinue clinical development of RG-101, a microRNA treatment for hepatitis C.
Contract Research & Services > Clinical Trials > News
Probiodrug unveils encouraging results of phase 2a SAPHIR study in AD patients
Probiodrug has reported positive results for its PQ912 candidate in a Phase 2a SAPHIR study in early Alzheimer’s disease (AD) patients.
Contract Research & Services > Clinical Trials > News
Merck and Pfizer's ertugliflozin meets primary endpoints in two type 2 diabetes studies
Merck, in partnership with Pfizer, announced that two phase 3 studies of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help enhance glycemic control in adults with type 2 diabetes, met their primary endpoints.
Contract Research & Services > Clinical Trials > News
AbbVie's rheumatoid arthritis drug succeeds in phase 3 study
By PBR Staff Writer
AbbVie's Upadacitinib (ABT-494) has met all primary and ranked secondary endpoints in a phase 3 trial in rheumatoid arthritis (RA).
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests